Perforating dermatosis in a patient receiving bevacizumab

MeSH terms

• Angiogenesis Inhibitors / adverse effects*
• Angiogenesis Inhibitors / therapeutic use
• Antibodies, Monoclonal / adverse effects*
• Antibodies, Monoclonal / therapeutic use
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents / therapeutic use
• Antineoplastic Combined Chemotherapy Protocols / administration & dosage
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• Bevacizumab
• Camptothecin / administration & dosage
• Camptothecin / analogs & derivatives
• Cetuximab
• Colorectal Neoplasms / drug therapy
• Colorectal Neoplasms / pathology
• Fluorouracil / administration & dosage
• Humans
• Leucovorin / administration & dosage
• Liver Neoplasms / drug therapy
• Liver Neoplasms / secondary
• Male
• Middle Aged
• Organoplatinum Compounds / administration & dosage
• Skin Diseases / chemically induced*
• Skin Diseases / diagnosis*
• Skin Diseases / pathology
• Treatment Outcome